Monday, September 14, 2026

Hanwha Ocean Partners with Leidos to Revolutionize U.S. Naval Shipbuilding – What This Means for the Future

Hanwha Ocean partners with Gibbs & Cox to enhance U.S. naval shipbuilding, focusing on design optimization and supply chain integration.

“Why Can’t Stem Cell Treatments Be Offered in Korea?”…Government Maps Out a “Korean Model of Regenerative Medicine”

The debate over stem cell therapy highlights why it's available in Japan but not in South Korea.

Palantir Hits New Record High Amid AI Surge, Surpassing Samsung’s Market Cap

Palantir's stock surged over 5%, reaching a record high of $116.65, driven by strong earnings and growing private sector demand.

Tag: biosimilar

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Celltrion’s CT-P51: Will This Keytruda Biosimilar Disrupt the 44 Billion USD Cancer Drug Market?

Celltrion has applied for approval of its biosimilar CT-P51 for the global blockbuster immuno-oncology drug Keytruda (pembrolizumab).

Celltrion Publishes Population Pharmacokinetic Analysis of Vegzelma in International Journal

Celltrion has published integrated population pharmacokinetic analysis results for its Avastin biosimilar Vegzelma, confirming pharmacokinetic similarity with the reference drug.

Samsung Bioepis Signs Teva Deal to Commercialize Opuviz in Canada, Expanding North American Biosimilar Business

Samsung Bioepis partners with Teva to launch ophthalmology biosimilar Opuviz in Canada, enhancing access to treatments for patients.

Celltrion’s Truxima becomes first rituximab biosimilar in U.S. to receive interchangeability designation

Celltrion's Truxima gains FDA interchangeability status, enhancing its market position and credibility in blood cancer treatment.

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

Daewoong Pharmaceutical Expands Biosimilar Push With Dupixent Copy Deal and Global CDMO Partnership

Daewoong Pharmaceutical partners with Chime Biologics to develop a Dupixent biosimilar, enhancing its global biosimilar business expansion.

A 90-Minute Cancer Infusion Could Soon Be Cut to 5 Minutes—and Celltrion Wants to Lead It

Celltrion has applied for EMA approval of Herzuma SC, a new breast cancer treatment, enhancing drug delivery and patient convenience.

Stoboclo: How This New Osteoporosis Treatment Achieved 11.8 Billion KRW in Sales in Just One Year

Daewoong Pharmaceutical's Stoboclo, a biosimilar for osteoporosis, achieved 11.8 billion KRW in sales in its first year, marking rapid growth.

Celltrion’s CT-P55: What Changes to FDA Clinical Trials Mean for Biosimilarity with Cosentyx?

Celltrion has applied to the FDA for changes to its Phase 3 trial of CT-P55, reducing participants to 153 to assess biosimilarity to Cosentyx.

How Celltrion’s Herceptin Biosimilar Herzuma Achieved 74% Market Share in Japan: A Game Changer for Cancer Treatment

Celltrion's Herzuma biosimilar captures 74% of Japan's trastuzumab market, enhancing patient access and leveraging favorable policies.

Samsung Bioepis Secures U.S. Approval for Pen-Style Stelara Biosimilar, Setting a Market First

Samsung Bioepis receives FDA approval for Epyztek, the first pre-filled pen for autoimmune treatments, enhancing patient convenience.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.